Related Experiment Video

Updated: Aug 9, 2026

The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension
05:57

The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension

Published on: May 17, 2024

Rosuvastatin attenuates hypertension-induced cardiovascular remodeling without affecting blood pressure in DOCA-salt

David Loch1, Scott Levick, Andrew Hoey

  • 1Department of Physiology and Pharmacology, School of Biomedical Sciences, The University of Queensland, Australia.

Journal of Cardiovascular Pharmacology
|April 25, 2006
PubMed

Insights

Rosuvastatin reduced cardiovascular remodeling, inflammation, and fibrosis in hypertensive rats. However, it did not affect blood pressure or vascular dysfunction, suggesting targeted benefits beyond blood pressure control.

Area of Science:

  • Cardiovascular Research
  • Pharmacology
  • Hypertension Studies

Background:

  • Hypertension often leads to end-organ damage, including cardiovascular remodeling.
  • Statins possess pleiotropic effects with potential therapeutic applications beyond lipid-lowering.
  • The DOCA-salt rat model mimics key features of human hypertension and associated complications.

Purpose of the Study:

  • To investigate the effects of rosuvastatin on cardiovascular remodeling in a DOCA-salt hypertensive rat model.
  • To determine if rosuvastatin can mitigate hypertension-induced cardiac hypertrophy, inflammation, fibrosis, and endothelial dysfunction.
  • To assess the impact of rosuvastatin on ventricular action potential duration in this hypertensive model.

Main Methods:

  • Male Wistar rats underwent uninephrectomy (UNX) and received DOCA (25 mg) with 1% NaCl in drinking water to induce hypertension.
  • Rosuvastatin (20 mg/kg/d) or vehicle was administered orally for 32 days, starting before UNX.
  • Cardiovascular parameters including hypertrophy, inflammation, fibrosis, endothelial function, and action potential duration were assessed at 28 days.

Main Results:

  • DOCA-salt rats exhibited hypertension, cardiac hypertrophy, inflammation, fibrosis, and prolonged action potential duration compared to controls.
  • Rosuvastatin treatment attenuated cardiac hypertrophy, inflammation, fibrosis, and action potential prolongation.
  • Rosuvastatin did not significantly alter systolic blood pressure or vascular dysfunction in the DOCA-salt rats.

Conclusions:

  • Rosuvastatin demonstrates pleiotropic effects by attenuating cardiovascular remodeling in the DOCA-salt hypertensive rat model.
  • The beneficial effects of rosuvastatin in this model are independent of its impact on blood pressure.
  • These findings suggest rosuvastatin may offer protective benefits against hypertension-related cardiac damage through mechanisms other than blood pressure reduction.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...